

Biomarkers to Redirect Response to Ovulation Induction



Pablo Diaz-Spindola, MD, FACOG
Medical Director IECH Fertility Center Monterrey
Professor of Endocrinology and Reproductive Medicine
Fellowship of UNAM
Monterrey, Mexico



Objectives

Background

What is AMH


iCOS Biomarkers

Protocols

Discussion of advantages


Conclusions

Decrease of the Female Fertility Based on Age



Johnson RJ., and Wallace WH., Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. *Pediatr blood cancer* 2009;53:296-302.

Decrease of the Female Fertility Based on Age



Johnson RJ., and Wallace WH., Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. *Pediatr blood cancer* 2009;53:296-302.

Risk Factors that Decrease the Ovarian Reserve



The American College of
Obstetricians and Gynecologists
WOMEN'S HEALTH CARE PHYSICIANS

**Reproductive older (over 35 years).
Family history of early menopause.
Genetic conditions (eg. Mosaic 45 X)**

**Permutation of the FMR1 (fragile X)
Conditions that can cause ovarian damage
(eg. Endometriosis, pelvic infection)
after ovarian surgery**

**Oophorectomy
Medical history of use of medicinal
gonadotoxics
smoking**

**Wait... What is all
this about.**

Redirect Response to
Ovulation Induction



gfa
Global Fertility
Academy

Biomarker: Definition

- NIH “ A characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention”

Objective for Having an Ovarian Biomarker

- Avoid excessive response and reduce ovarian responses.
- Identified poor responders to diminish cycles cancellation.
- Facilitate an optimal treatment strategy, potentially minimizing complications and the risk of treatment failure
- Reduce the cost


Women Always Want to be a Little Different....



Poor Responder
AMH 0.2 ng/ml



Normal Responder
AMH 1.9 ng/ml



Hyper Responder
AMH 3.6 ng/ml


So, we need to act differently.

How Easy is the IVF Treatment?




The way we would like it. The way it really is.

Our Focus are Biomarkers, but There are so Many Factor...



**Which one is the best
Biomarker to define
ovarian response?**



Discovered 1940 by Alfred Jost
Müllerian inhibiting substance

Human Gen

- 20 years later it was isolated and his sequence was known.

Homodiméric
Glycoprotein

- Molecular weight 140 kDa
- 4 times heavier than FSH and LH
- Gene on chromosome 19 p13.3

TGF- β

- It belongs to the super family of beta transforming growth factor

0163-768X/01/803.00/0
Printed in U.S.A.


Endocrine Reviews 22(5):657-674
Copyright © 2001 by The Endocrine Society

Müllerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications

JOSE TEIXEIRA, SHYAMALA MAHESWARAN, AND PATRICIA K. DONAHOE

Pediatric Surgical Research Laboratories, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114

Physiology of AMH



Secreted by the primordial and prenatal follicle granulosa cells.

- They lose this ability from antral follicles (6-8 mm), mediated by FSH.
- The number of follicles in growth are those that produce the AMH.
- Effect on the primordial follicles remaining, inhibiting their recruitment.

Stability of the AMH

Factors that could influence on the serum concentration of AMH:

Reduce it:

Age

BMI

Administration of
chemotherapy and
radiotherapy
Oophorectomy

Increase it:

PCOS

Have no influence:


Menstrual cycle

GnRh agonists

oral contraceptives

pregnancy

AMH Assays



Broer S.L. Et cols. Anti-müllerian hormone: Ovarian reserve testing and its potential clinical implications. Human reproduction update 2014;20(5):688-701.

Characteristics of the Most Commonly Used Markers of Ovarian Reserve



The American College of
Obstetricians and Gynecologists
WOMEN'S HEALTH CARE PHYSICIANS

Test	Details
FSH plus estradiol	<ul style="list-style-type: none">• Serum level on cycle day 2–3• Variation between cycles possible• High FSH value is associated with poor response to ovarian stimulation• Does not predict failure to conceive
AMH	<ul style="list-style-type: none">• No specific timing for the test• Stable value within and between menstrual cycles• Low AMH value is associated with poor response to ovarian stimulation• Does not predict failure to conceive
AFC	<ul style="list-style-type: none">• Number of visible follicles (2–10 mm) during transvaginal ultrasound• Performed on cycle days 2–5• Number of antral follicles correlates with ovarian response to stimulation• Does not predict failure to conceive

Abbreviations: AFC, antral follicle count; AMH, antimüllerian hormone; FSH, follicle-stimulating hormone.

Ovarian Reserve Testing. The American College of obstetricians and Gynecologist. Committee Opinion. January 2015, Number 618.

Markers of Ovarian Reserve and its Influence on Pregnancy

Assessment	Outcome	
	Favourable	Unfavourable
Prior COH cycle	Delivery	No pregnancy
Age (years)	<35	≥35
FSH (IU/l) ^a	<10	≥10
d3 E ₂ (pg/ml)	<75	≥75
d10 P ₄ ^b	<0.9	≥1.1
AMH (pmol/l) ^c	15.7–48.5 ^e	<15.7
d3 inhibin-B (pg/ml) ^d	>45	≤45
AFC ^e	≥5	<5
Ovarian vascularity	Lower PI	Higher PI
Ovarian volume (cm ³) ^f	≥3	<3
CCCT [FSH only (IU/ml)] ^g	<12	≥12
GAST	Early E ₂ flare	Persistent E ₂ ↑ or no response

Sills ES., Alper MM., Walsh PH., Ovarian reserve screening in infertility: Practical applications and theoretical directions for research. European journal of obstetrics and gynecology and reproductive biology 2009;146:30-36.



Comparative Table of More Common Characteristics of the Ovarian Reserve Markers

Characteristics for a Good Marker	Age	AMH	FSH	AFC
Prediction of poor response	+	+++	++	+++
Prediction of hyper response	+	+++	+	+++
Low inter-cycle variability	+++	++	-	++
Low intra-cycle variability	+++	++	-	++
Applicable to all patients	+++	++	+	+
Economic	+++	-	-	-

-, not appropriate; +, not very appropriate; + + +, very appropriate. AFC, antral follicle count; AMH, anti-Mullerian Hormone.


La Marca A., Sunkara SK., Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human reproduction update 2014;30(1):124-140.

Both Technologies are Improving and Increasing Accurate



Deb S, et al. *Ultrasound Obstet Gynecol.* 2009; Van Disseldorp, et al. *Hum Repro* 2009; Wallace, et al. *Ann Clin Biochem.* 2011; Nelson, et al. *Fertil Steril.* 101:523-529, 2014.

Markers of Ovarian Reserve of Today



La Marca A., Sunkara SK., Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human reproduction update 2014;30(1):124-140.

Normal Values Ovarian Reserve

Non-response: <1.1 pmol/l

Poor responder: 1 – 5 pmol/l or <0.5 ng/ml

Normal responder: 5 – 15 pmol/l or 1.0-3.5 ng/ml

High responder: >15 pmol/l or >3.5 ng/ml

Fleming R. Et cols. Can Anti-Mullerian hormone concentrations be used to determine gonadotrophins treatment protocol for ovarian stimulation? Reproductive BioMedicine Online (2013) 26, 431. 439

Toner JP., et cols. Why we may abandon basal FSH testing: a sea change in determining ovarian reserve using AMH. Fert Stert 2013;99:1825-30.


AMH Conversion Factor



1 ng/ml = 7.143 pmol/l

Somebody explain me, please.

Strategic Modelling of Controlled Ovarian Stimulation on the Basis of Ovarian Reserve Markers




Nelson et al. (2009)

Yates et al. (2011)


La Marca A., Sunkara SK., Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human reproduction update 2014;30(1):124-140.

Is This Nomogram Useful?




La Marca A., Sunkara SK., Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Human reproduction update 2014;30(1):124-140.

Can We Relate AMH to COS Protocols?




High Responder Patient




- Definition >15-20 oocytes
- AMH > 20 pmol/l
- PCOS type
- History of OHSS
- Therapy suggested:
 - Antagonist protocol
 - rFHS alone
 - 100-125 IU/d
 - Eventually agonist triggering
 - Freeze all strategy

Normal Responder Patient




- Definition 8 -15 oocytes
- AMH 7-19.9 pmol/l
- History of normal response
- Therapy suggested:
 - Antagonist protocol
 - rFHS alone
 - 150-225 IU/d
 - hCG triggering

Low Responder Patient



- Definition 5 -8 oocytes
- AMH 1.1-6.9 pmol/l
- Women <40 years of age
- History of Low response
- Therapy suggested:
 - Antagonist protocol
 - rFHS and LH
 - 300 IU/d FSH + 75-150 IU/d
 - hCG triggering

Poor Responder Patient



- Definition <5 oocytes
- AMH < 1.1 pmol/l
- Negligible chance of response
- Therapy suggested:
 - Antagonist or flare-up agonist protocol
 - 300 IU/d FSH plus 150 LH
 - hCG triggering

Not all agree

Predictor of Response in ART

Most useful tool when evaluating the ovarian reserve (fertile and infertile).

More specific prediction than FSH


Inter- and intra-ciclo variability and stability make handy tool. 6-8 months

AMH serum levels correlate more with CFA than other markers in day 3 of cycle (FSH, LH, estradiol and inhibin B).




Detection limit 0.05 ng/ml

Predictor of Response in ART



Kunt C, et al. Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization. Arch Gynecol Obstet. 2011;283:1415-21

Predictor of Pregnancy



Predictor of Ovarian Response

HAM as ovarian predict response
sensitivity 82% and specificity 76%

- AFC sensitivity 82% y Specificity 80%.

Low response <1.0 ng/ml

- 2-30% will be low responders.
- Lower pregnancy rates compared with normoresponders of the same age.
- Premature ovarian failure

(OHSS) ovarian hyperstimulation syndrome. >3.75 ng/ml

- Moderate: 15-20%
- Severe: 1-3%.
 - Poor quality eggs
 - Hiperestimulados cycles can cause multiple organ failure.
- AMH predicts OHSS
 - sensitivity of the 90.5%
 - specificity of the 81.3%

HAM Values Used in Mexico as Predictors of Response



Cuadro 1. Características demográficas y bioquímicas de la población

	<i>Normorrespon- dedora (6-15 OC, n=20)</i>	<i>Hiporres- pondedora (≤5 OC, n=10)</i>	<i>Hiperrespon- dedora (≥16 OC, n=9)</i>	<i>P</i>
Edad	35 ± 6	37 ± 7	35 ± 5	0.667
AMH(ng/ml)	1.46 ± 1.43	0.355 ± 0.33	3.10 ± 1.86	0.015*
FSH (UI/L)	7.40 ± 3.53	10.37 ± 9.23	5.53 ± 1.62	0.146
AFC en FFT	7.8 ± 2.4	1.6 ± 1.1	16 ± 2.2	<0.01**

Media ± desviación estándar (DE).

*Normorrespondedoras vs hiperrespondedoras

** Normorrespondedoras e hiperrespondedoras vs Hiporrespondedoras

AMH Values Used in the IECH as Predictors of Response





TABLA No. 1	0-5 OVOCITOS (n=10)	6-16 OVOCITOS (n=26)	17 O MÁS (n=12)	Valor P
Edad	38.8± 3.58	27.69±6.94	27.6±7.67	<0.000
IMC	22.53±4.33	24.64±4.31	23.47±2.95	0.344
FSH	8.78±3.43	5.22±1.65	4.55±1.70	<0.000
Estradiol día 10	555.10 ±489.64	2416.27±1428.44	3564.75±1678.39	<0.000
Folículo > 15 mm	2.30±1.89	9.54±3.89	11.58±2.31	<0.000
HAM	0.59±0.40	2.27±1.36	4.74±1.97	<0.000
Ovocitos Totales	2.50 ±2.17	11.73±1.19	20.08±2.64	<0.000
Ovocitos Maduros	2.30±2.11	9.15±3.45	15.17± 3.83	<0.000

Mojica-Martinez K., et al. Correlation between serum AMH, day 3 FSH and response to controlled ovarian hyperstimulation (COH) in a population of infertile Mexican patients. Fert Ster. 2011;96(3, Supl):S121.


Applications



Conclusions

- There are so many information about AMH as a biomarker for ovulation induction
- Today we can standardized level of AMH
- There are many protocols depends of AMH levels, and we need to avoid HOSS, and cancellation for poor responder patient.
- We would like to have always the “perfect patient with the perfect protocol” to help them to get pregnant.

Conclusions



Anti-Müllerian Hormone is an excellent biomarker of follicular reserve, however cannot be considered as a predictor of pregnancy

Gynecologic Concerns in childrens and adolescents with cáncer. The American Colleage of obstetricians and Gynecologist. Committee Opinion. August 2014 Number 607.

Nelson SM., Biomarkers of ovarian response: current and future applications. Fertil Steril 2013;99:963-969

Biomarkers to Redirect Response to Ovulation Induction



Pablo Diaz-Spindola, MD, FACOG
Medical Director IECH Fertility Center Monterrey
Professor of Endocrinology and Reproductive Medicine
Fellowship of UNAM
Monterrey, Mexico

